Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ITKG
I looked at this one and put it on a watchlist because I thought the technology looked nifty and thought the relationship with DuPont sort of validated the claims.
But while at a wedding a few weeks ago, I actually met a Dupont engineer that was familiar with the Dupont/ITKG collaboration. So I had to ask him if he had heard about ITKG. I couldn't remember the name of the company, but began explaining the concept to him....and he spouted out "Integral Technologies"....and I said that sounded right with the ticker ITKG. I was amazed he had even heard of ITKG, DuPont is HUGE, but the world is small. He didn't divulge any details or anything that could be considered "insider info."; but cautioned that DuPont has a lot of these LOIs that never lead to anything. He also made a general comment that sometimes these small companies are more eager to be able to use DuPonts name than to REALLY pursue any collaboration; but we all should realize this already. So essentially, he didn't discredit the technology, but just cautioned that the LOI with DuPont is nonbinding.
Now that I took a closer look at that PR, yes it's more obvious that this is a very vague collaboration. That doesn't mean I won't watch it to see how the situation develops; but I wouldn't consider it a good long-term play quite yet.
On the other hand, I really like BIPH because they are actually being paid by Boston Scientific for R&D, that's a bold statement to me.
I looked quite closely at AVII yesterday thinking it was near a bottom, but couldn't find any compelling reason to buy it, so I left it.
This has been typical of my luck lately. I have a knack for looking closely at good potential short-term gainers and passing over them only to buy the short-term loosers.
I bought more PHPG yesterday so be careful with it today...better buying opportunites ahead most likely, lol!
AVII news of a $10M federal funding. Catfish reccommended this a while ago; but I never bit. Gapping up this morning. I don't own any.
U.S. Senate Committee on Appropriations Directs $10 Million For Defense-Related Research to AVI BioPharma
Thursday June 24, 6:45 am ET
PORTLAND, Ore.--(BUSINESS WIRE)--June 24, 2004--AVI BioPharma, Inc. (Nasdaq:AVII - News), today announced that the U.S. Senate Committee on Appropriations has approved $10 million in funding for two AVI infectious disease projects, as a portion of the minimum $103.5 million in total funding for defense-related projects in Oregon for the 2005 fiscal year. AVI is designated to receive $6 million for the development of technology to test for and find therapeutic agents for viruses, including Ebola and Marburg viruses, as well as an additional $4 million specifically targeted for anthrax and ricin toxins.
"Our previous experience using our proprietary NEUGENE® antisense technology to develop drugs against viruses provides a solid framework for developing therapeutic agents against these potential bioterror agents," said Alan P. Timmins, president and COO of AVI. "In addition, we feel these appropriations are a credit to our Oregon Senators, Ron Wyden and Gordon Smith, and their diligence and dedication to funding bioterrorism defense, creating jobs and supporting biomedical research in the state of Oregon. This funding is truly an example of bipartisan teamwork at its best."
Through these awards, AVI will leverage its antisense antiviral work and its collaboration with the U.S. Army Medical Research Institute of Infectious Diseases to promote survival and favorable clinical outcomes following exposure to these toxins. These funds are now included in the government's fiscal year 2005 defense spending bill, which must now be approved by the full Senate. The company anticipates that the research for the Ebola/Marburg project and the anthrax/ricin project may take up to three years each with the company positioned to receive additional $10 million allocations in fiscal years 2006 and 2007, but government appropriations beyond the initial $10 million for fiscal year 2005 would depend upon ongoing successes and future legislative actions.
AVI believes its NEUGENE antisense "rapid response therapeutics" have a significant role to play in the future of bioterrorism defense. NEUGENE compounds are synthetic compounds that mirror a critical portion of a disease-causing organism's genetic code, which bind to specific portions of the target genetic sequence. Like a key in a lock, NEUGENE antisense compounds are designed to match up perfectly with a specific gene or viral sequence, blocking the function of the target gene or virus.
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: third-generation NEUGENE antisense drugs and cancer immunotherapy. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to target single-stranded RNA viruses, including West Nile virus, SARS coronavirus, calicivirus and hepatitis C. AVI's second technology, AVICINE®, is a therapeutic cancer vaccine with late-stage trials planned for the treatment of pancreatic cancer. More information about AVI is available on the company's Web site at http://www.avibio.com/.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
--------------------------------------------------------------------------------
Contact:
Company Contact:
AVI BioPharma, Inc.
Michael Hubbard, 503-227-0554
hubbard@avibio.com
or
Investor Contacts:
Lippert/Heilshorn & Associates Inc.
Bruce Voss or Jody Cain
310-691-7100
bvoss@lhai.com
jcain@lhai.com
or
Press Contact:
Waggener Edstrom Bioscience
Wendy Carhart, 503-443-7000
wendyc@wagged.com
NTRZ is going to be getting some national TV coverage, which could have a possitive impact on their sales eventually:
NutraCea to be Featured on Medstar Advances, a Nationally Syndicated TV News Segment Reaching Millions of Viewers
Wednesday June 23, 7:01 am ET
EL DORADO HILLS, Calif., June 23 /PRNewswire-FirstCall/ -- Nutracea® (OTC Bulletin Board: NTRZ - News), a leading nutraceutical company, announced today that its novel stabilized rice bran (SRB)-based products and innovative stabilizing technology will be the subject of a Medstar Advances (http://www.medstar.com) news segment that will air on over 60 major U.S. television networks as well as Discovery Channel, HBO, Court TV, The Learning Channel, regional cable networks and international programming. The stations received the segment this week and will begin airing it from now until the end of June. Each market is limited to only one network to ensure a broader coverage area.
"It's a very exciting time for us. Our proprietary stabilized rice bran- based formulas continue to undergo scientific scrutiny at leading academic institutions for coronary heart disease, arthritis and diabetes and anecdotal reports are also pouring in as more and more people are reaping the health benefits of this nutrient-rich medical-grade rice bran. Now the media is catching on that this is quite possibly one of the most important medical discoveries in human nutrition in the past decade," said Patricia McPeak, CEO and Inventor of SRB.
Nutracea recently announced that they won the Nutraceutical's World Industry Innovator Award and were featured as one of seven finalists in the July issue. Their stabilized rice bran formulas will also be mentioned in upcoming issues of other nationally circulated publications like Vegetarian Times, First for Women, Alternative Medicine and Nutrition Business Journal.
About Medstar
Medstar Television, Inc. is America's leader in televised medical news and health information in business since 1980. Medstar provides innovative programming to broadcast stations and cable networks worldwide through their staff of award-winning medical journalists and television news professionals. The company serves broadcasters from all major U.S. television networks, as well as Discovery Channel, HBO, Court TV, The Learning Channel, regional cable networks and international programmers.
About Nutracea
NutraCea (OTC Bulletin Board: NTRZ - News) is focused on becoming one of the world's leading nutraceutical companies through the development and distribution of its proprietary stabilized rice bran "super foods," natural arthritic relief products for humans and animals and "all natural" cosmeceuticals and beauty aids. The company is headquartered at 1261 Hawk's Flight Court, El Dorado Hills, California 95762.
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission including the company's Annual Report, Quarterly Reports and other periodic filings. These forward- looking statements speak only as of the date hereof. Actual sales of products may differ or vary from estimates as per the statement herein. The company disclaims any intent or obligation to update these forward-looking statements.
FDA Health Disclaimer: NutraCea's product-related statements have not been evaluated by the Food and Drug Administration. The company's products are not intended to diagnose, treat, cure or prevent any disease. Consult your physician before using any nutraceutical products.
To learn more about NutraCea's products, visit http://www.nutraceacorp.com.
To sign up for shareholder alerts, visit http://www.nutraceacorp.com/ir_alerts.html or simply send an email to alerts@nutraceacorp.com. For a shareholder package, visit http://www.nutraceacorp.com/ir_iik.html.
Public Relations Contact:
Adelman Communications
Margie Adelman (561-347-6768 office or 561-866-2215 cell)
CNBC is going to have a spot at 2:30 p.m. today on Cablevision's VoIP services. What's this have to do with any of the microcaps we follow?
PSOL has Time Warner cable as a customer for their VoIP product and they have another "unnamed Teir I Cable MSO customer". Since Cablevision and Time Warner are the only cable companies offering VoIP, I think Cablevision could be the other PSOL customer?
Here's a good post from RB:
By: TALLPAUL_30
05 May 2004, 03:35 PM EDT
Msg. 1018 of 1194
Jump to msg. #
Eureka, I have found it .... I think?
From C/Net News.Com, November, 2003 Publication
"Most U.S. cable providers are launching VoIP plans to challenge the telephone companies' stranglehold on the local and long-distance phone market. Cablevision is the second major U.S. cable provider to make a bigger commitment to VoIP in less than a month."
"In late October, Time Warner Cable announced plans to expand its "Digital Phone" service to four more cities."
"Meanwhile, the nation's top cable broadband providers, Cox Communications and Comcast, are still testing the technology, and both say they won't implement it until at least late next year."
It has to be Cablevision, since they announced their VOIP rollout in November, 2003.
Cox and Comcast are deferring until late 2004, or possibly later, plus Adelphia won't consider it while still in Chapter 11.
Their is no one left to qualify as "the other tier 1 Cable MSO", because they're the Big 5.
Cablevision is offering their VOIP service to 1,000,000 high-speed internet customers in the lucrative NYC Metro market.
It only gets better for the home-team.
TP
BSDM had a slug ov volume go through today. I got a little @ $1.60 and just upped my order to $1.65.
Cat good call on STKR volume this morning at 2.40/2.42. I only watched so far; but if it settles back down around there I think I might get in this time....it seams to be a very predictable pattern here with them.
DCTH had nice volume into the close today. Might be an indication there's good news coming soon...maybe?
Catfish, the STKR volume seams to be parallel to the volume in IPIX, TBUS, and MACE related to a speech Tom Ridge gave in Oak Ridge today that apparently mentioned IPIX:
http://finance.yahoo.com/q/bc?s=IPIX&t=1d&l=on&z=m&q=l&c=trbus,mace,stkr,tbus
BIPH and Boston Scientific news!!! Man it felt like I waited forever for this; but I'm sure it sure was worth the wait. I have about 70% of my brokerage account in BIPH and about 15% of my IRA....Tuesday is going to be incredible!!!
Boston Scientific and Biophan Expand R&D Relationship
Friday May 28, 4:01 pm ET
Companies to Extend Joint Development Program to Multiple Products
ROCHESTER, N.Y--(BUSINESS WIRE)--May 28, 2004--Biophan Technologies, Inc. (OTCBB:BIPH - News), a leading developer of next generation biomedical technology, announced today that it has completed Phase I of a three-part joint development program with Boston Scientific (NYSE: BSX - News), a medical device company with a $32 billion capitalization. Sales for Boston Scientific reached $3.75 billion over the last year and are on a run rate of over $5 billion for 2005. The program involves exploring the use of Biophan's cutting-edge, MRI safe and image compatible technologies with a variety of Boston Scientific products.
The companies have already begun the next two phases, in which Biophan will receive additional payments and will extend Boston Scientific's first right to negotiate the licensing of Biophan technologies that result from the companies' joint development efforts. In addition, the companies are exploring ways to further expand their relationship by providing access to Biophan's technologies for additional products.
"We are extremely pleased to be aligned with a company the size of, and with the marketing strength of Boston Scientific," stated Michael Weiner, CEO of Biophan. "Not only have we received funding contributing to evaluating our technologies, we also have been able to interact with one of the most innovative and forward thinking companies in the medical device sector. The access to Boston Scientific personnel has significantly helped us hone our solutions to meet the needs of the medical device industry, including identifying new applications that can benefit from MRI safety and image compatibility."
About Biophan Technologies
Biophan Technologies develops and markets cutting-edge technologies designed to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tools--safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents. Committed to growth through innovation and developmental leadership, Biophan and its licensors have nine issued U.S. patents and over fifty patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, and photonics. Biophan's technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI. For more information, please visit www.biophan.com.
About Boston Scientific Corporation
Boston Scientific is a worldwide developer, manufacturer, and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
--------------------------------------------------------------------------------
Contact:
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Michael Weiner, 585-214-2441
It does re-emphasize the importance of sharing information on these message boards. I saw kirby and rufff's posts yesterday on SI; but just had no idea POSC could pull off something this good!
This also re-emphasizes the importance of volume as an indicator. You helped me enjoy the move in SSPI, and BOCX by posting volume alerts.
Volume on PSOL was also prety significant with 6x average volume. I almost bought more at the close yesterday for a quick move; but that didn't happen yet?
POSC: I've sat on this for years...thought it was going to be a write off some day. I can't believe the action today...incredible....out of no where. Wish I would have listened to the volume indicators yesterday....but no....I just sat and watched....so all I have is my 1,700 shares from $0.07 a few years ago. Man this move should have been ours! GPG and the Microcap Kitchen has been following this one for years!
Stewart re: BIPH.ob:
No PR yet about BSX; but this was said during the BIPH investor CC:
"....Then, devices used in interventional medicine like the 48-inch long, stainless steel guidewires that are used to implant stents, these procedures are done under X-ray and the installing physicians are exposed to ionizing radiation, which is dangerous. They wear heavy lead aprons, which unfortunately, causes many of them to have back problems. So the question you might ask logically is, why don't they do these procedures under MRI where there is no ionizing radiation, and where you can see better soft tissue and better see this metal device that's being threaded through your vascular system?
The reason why is that, these guidewires both have a safety issue, they get hot and they blacken the image out. Now in the guide wire area, we've pretty much cracked the code on solving both of these problems and that not only is good for Biophan and our customers when they make MRI safe guidewires, but it could open up a whole new field of interventional medicine, which could be very beneficial to the MRI device manufacturers and to the physicians and to the patients. So these technologies have a fairly significant impact long-term on the healthcare industry. This, of course, will be very good for the Biophan shareholders.
This puts us in a very unique position in another interesting way. We are actively involved, mostly under confidentiality agreements, with many of the R&D and new business development people in most of the larger biomedical device companies. We have announced that we have a joint development agreement with Boston Scientific, which is going well and has moved into the second phase and is expanding into more product lines and we'll have information in the future with them on the status of that relationship.
I find it odd coinsidence that he brought up BSX and the expanded product lines, right after that very optomistic discussion of their work with stents and guidewires....I hope I am not reading into this too much; but man does that make me optomistic for the long-term.
This was also said:
"D. Eritt
Hello, Mr. Weiner. Congratulations on your company and the success you've had so far. I have one question about the next phase with Boston Scientific, any timeline for that?
M. Weiner
We've already moved into the next phase as I mentioned earlier; and the way these things work is that they and we have a shared interest in making certain products of theirs more competitive and more beneficial for patients. It is hard to predict exactly when during the R&D phase that you get to the point of comfort, where you want to make a decision in their case, to further extend their exclusive options or to commit a product to market.
Then, it's very hard for us to share with you where we really are because very often, these things are being done for competitive advantage purposes and you don't really want to signal to the competition too quickly, exactly what you're doing and when you'll get there. It may seem fairly vague with specifics, but you will be hearing more news about our relationship with them, and it is going forward."
As I read the SEC 8k rules, I would have thought that a change to the agreement would have needed to have been released in an 8k. I e-mailed the company with this question, citing the 8k disclosure rule changes from 3/04 and IR replied that they believe they are in compliance with those disclosure rules....so I guess we need to be patient?
The Cohen report was paid by the company, but from the www.Cohenresearch.com website, it looks like these reports get pretty wide distribution. It was probably a good move by the company to help build the audience of investors. I really believe the company is doing everything it can to improve market awareness before a big news item is released.
After a brief glance at LTHU.ob, I'm not seeing too much to get excited about? What's the story there?
No problem, I'm glad to have something to contribute.
tincup/GPG what do you think of MYMX recent developments?
I saw you post the 8k announcing the successful test results with protienXpert SA in April. I did some DD and decided I liked it for a long shot, high risk/high reward situation. As their last Q said "Despite limited means and impressive hurdles to overcome, we have been able since July 31, 2003 to graduate from an assured crash to a (still) bumpy ride". It's not too often that I get a laugh while reading SEC repots, but I was hysterical after reading that statement! That's some brutal honesty! Keeping with that metaphor, I think they may have just turned off the seat belt sign and we are now free to move about the cabin, lol!
You probably saw the recent 8k reports indicating MFIC has extended the 3.2M Euro debt to 12/31/2004 for the fee of 500,000 144 restricted shares. These actually seam like pretty favorable terms IMO. The 500k shares @ $0.15 is $75k, which roughly equates to about 4.5% APR on the 3.2 Euro balance (assuming 1 EU = $1.15....and term of 6 mos.). Then consider that the 144 shares are restricted for at least one year and the loan extension is only for 7 months....this almost looks like a vote of confidence from the bank....or at least some incentive for the bank not to force liquidation until after 5/11/05. Am I missing anything?
I am also encouraged by the fact that the private placement investors have exercised their $0.10 options early (and don't seem to be in a hurry to sell).
If you haven't seen these posts on RB, they might be of interest to you:
Summary of phone conversation with CFO:
http://ragingbull.lycos.com/mboard/boards.cgi?board=MYMX&read=187
Mymetics and protienXpert are presenting at BIOtechno2004 in Rhone, France on 6/4/04:
http://ragingbull.lycos.com/mboard/boards.cgi?board=MYMX&read=210
As always, thanks for sharing your hard work. I don't know how you find so many good companies so early; but I appreciate the opportunites you find!
This stock might light up sometime soon! The company has ousted the former BOD, successfully completed a test of gp41 with proienXpert SA, done a few private placements for roughly 4M shares @ $0.10, extended repayment of debt to MFIC Bank until 12/04 by giving MFIC shares that are restricted for a year!?!? The last 10Q said they are in discussions with major pharma companies pending initial results of the gp41 compound...which I think might be the tests they successfully completed in April?
They are also presenting at BIOTechno2004:
http://translate.google.com/translate?hl=en&sl=fr&u=http://www.biotechno.asso.fr/Pages/Ville...
14h00 – 14h30 Presentations Flash d’entreprises
Nucleis, Dynal Biotech, Protein’expert, Mymetics, Genzyme, IdealPharma
Here's the 5/11/2004 8K:
NEW 8-K:
http://biz.yahoo.com/e/040511/mymx.ob8-k.html
Other Events
ITEM 5. OTHER EVENTS.
On May 11, 2004, MFC Merchant Bank SA agreed not to request repayment of the ME3.2 loan granted to Mymetics Corporation before December 31, 2004, under the condition that we issue the bank 500,000 common shares (with a 144 restriction) of Mymetics Corporation as a remuneration for this extension.
The repayment of this loan, which is collateralized by a lien on essentially all of our patents portfolio, was previously due on June 30, 2004, as more fully disclosed in our Form 10-Q for the period ended September 30, 2003.
Catfish re: the discussion about naked shorting on SI....I don't think this article has been posted:
=DJ IN THE MONEY: German Brokerage, Exchange Deny Wrong Doing
By Carol S. Remond
A Dow Jones Newswires Column
NEW YORK (Dow Jones)--Berliner Freiverkehr AG, a large German brokerage firm
and the Berlin-Bremen Stock Exchange are disputing claims by some small U.S.
companies that their shares were improperly listed on that exchange.
Some development stage U.S. companies, which usually crave international
recognition and on occasions have paid to be listed on foreign stock exchanges,
are now seeking for their stocks to be removed from the Berlin exchange.
These companies, most of which have shares that trade in the U.S. on the
Over-The-Counter Bulletin Board, claim in press releases that their shares were
listed without proper authorization and without their knowledge. Some also
stated that the listings, most of which were sponsored by Berliner Freiverkehr,
were designed to circumvent tougher short selling rules recently enacted by the
NASD.
But Holger Timm, founder and chief executive officer of Berliner Freiverkehr,
said the recent listing of about 1,000 U.S. OTCBB companies on the Berlin
exchange had nothing to do with U.S. rules governing short selling. Rather, Timm
said, his firm's decision early this year to sponsor the listings on the Berlin
exchange came because of tighter reporting requirements in the U.S. for these
companies.
"We have been doing this for 20 years. We trade regulated stocks from all over
the world in Germany," Timm told Dow Jones Newswires in a telephone interview.
Timm said his firm requested the listings because reporting requirements for
OTCBB companies in the U.S. are more stringent than those for blue-chip
companies listed in Germany. He said his firm selected Berlin, rather than
Frankfurt or other German exchanges, because listing there is free.
Timm said that claims by some U.S. companies that their shares were illegally
shorted in Germany are unfounded because "it's impossible to sell short here.
All we do is bring the two markets together." Timm explained that a stock
transaction normally involved a German investor looking to buy U.S. stocks using
euros. Following that order, Berliner Freiverkehr typically turns around and
purchase the shares in the U.S., saving the German investor fees.
Timm said that under German rules, German brokerages don't have to ask
permission to foreign firms to list them. "What we do is send them letters
informing them about the listings and telling them about the advantages" of
trading on the Berlin exchange, Timm said. He said that about 10% of those
letters come back undelivered because of wrong addresses.
Timm said his firm has received letters from U.S. companies complaining about
the recent listings on the Berlin exchange. "We got letters from different
companies using the same wording. I guess some lawyers out there are telling
them to do it."
Timm said that because the listings were recent and hadn't been publicized,
most of OTCBB companies listed had little or no volume on the Berlin exchange.
A spokeswoman for the Berlin stock exchange said in an email that all trading
of international shares on that exchange "is legal and according to rules."
"Trading in the third market on the Berlin Stock Exchange is free of charge.
The daily process of listing new companies is routine for us. So every day we
have a lot of new companies in the pipeline," she said.
The spokeswoman said the exchange is in contact with the Securities and
Exchange Commission and checks all accusations by U.S. companies.
"On request of the SEC we examined the prices made on our exchange for some
companies. We came to the conclusion that none of these cases involved short
selling. In some cases, share prices went up due to a majority of buy orders.
Interestingly enough, in those cases where companies blamed the trading on the
Berlin Stock Exchange for falling prices, our investigations revealed that the
securities were either not yet traded on our exchange or that no trading took
place at all during the relevant period," she said.
A spokesman for the SEC declined to comment.
The NASD in April toughened rules governing short selling of U.S. stocks,
extending its affirmative determination rule to non-NASD members such as
specialists, option markets and foreign brokers.
The affirmative determination rule stipulates that brokers and dealers engaged
in a short sale transaction must make sure that shares can be delivered by
settlement time, three days later. Bona fide market making transactions are
exempt from affirmative determination.
A short seller typically borrows stock from a broker to sell it into the
market, betting that the share price will fall so that he can buy the stock back
at a lower price and pocket the difference.
A spokesowman for the NASD declined to comment.
Some have suggested that foreign listings could be used by U.S. market makers
to circumvent the affirmative determination requirement given that bona fide
intermarket arbitrage is exempt for such requirement. Berliner Freiverkehr's
Timm said no NASD members or brokerages ever requested the listing of U.S. OTCCB
companies on the Berlin exchange. Timm also pointed out that the absence of
trading volume on the Berlin exchange would curtail any possible benefit for
U.S. market makers or short sellers.
Timm said he had been in touch with U.S. companies that complained about the
listings. "If they want to be delisted, we will delist them in Berlin. But if
they are listed on other exchanges it's out of my control," he said.
Among companies that recently announced that they requested to be removed from
the Berlin exchange are: DataMeg Corp. (DTMG); MultiCell Technologies Inc.
(EXTI); TS&B Holdings Inc. (TSBB); Odyssey Marine Exploration Inc. (OMR) and
FemOne Inc. (FEMO); Reclamation Consulting & Applications Inc. (RCAA); Dicut
Inc. (DCUTE) and Whistler Investments Inc. (WHIS).
Most development stage companies in the U.S. have traditionally sought out
listings on foreign exchanges to promote their businesses and secure much needed
financing by selling shares to foreign investors in private placements which are
often less regulated abroad than in the U.S.
But some companies appear confused over the foreign listing of their shares.
ICOA Inc. (ICOA), a company that on April 28 heralded its listing on the Berlin
exchange, saying its "recognition by the international financial community is a
validation of our recent progress as well as our future potential". However,
just a week later, it requested a delisting.
(Carol S. Remond is one of four "In The Money" columnists who take a
sophisticated look at the value of companies and their securities and explore
unique trading strategies.)
-By Carol S. Remond; Dow Jones Newswires; 201 938 2074;
carol.remond@dowjones.com
(END) Dow Jones Newswires
26-05-04 2053GMT
Jeff, Maybe we had a good day today because terp wasn't able to scare the nervous nellies with his lies on RB :) I say keep RB down...and let's all quietly migrate here...and leave terp and boca to themselves :) I guess the problem with that idea is that RB has much more of an audience than I- hub does....at least for now.
There's another message board here on I-Hub where we discuss a lot of good microcap stocks, including BIPH. It's sort of a parallel board to the Silicoln Investor Microcap Kitchen. Feel free to stop over and check it out if you're interested:
http://www.investorshub.com/boards/board.asp?board_id=2025
Good call on SSPI again. BIPH and ISON are both moving up on news today. AIDO had some good news; but I don't own it. PFCE moving up nice on no news...but I missed the bottom there too.
ISON is slipping back to the $1.40s today. BIPH is slipping back to the low $1.00 range.
SIGA is getting a lot of coverage based on the BioShield Bill. It would have been a great play from when you mentioned it on SI a few weeks back; but now I'm a little hesitant to chase it.
Catfish I'm in ISON from $1.60 and held it through yesterday. I should have taken a profit at $1.90; but thought the volume was going to push it higher. With 10M shares in the float I don't understand how a 6M volume day doesn't move that stock more?
I'm hopeful that "major semiconductor company" testing their Si-32 will place an order some day.
ugh!!! eom
BIPH: 735,000 volume. Consolidation in the $1.25-$1.27 range. I would have expected this much volume to move the PPS up a bit more? I'm still holding for the conference call and BSX news; but am a little discouraged by todays trading action....should be moving up more IMO.
Good day for BIPH on a bad day for the market!
Catfish I also spoke with ADGO; but I spoke to the IR women, Patty Walsh. Someone on the RB board, with the handle "JII", said he was also going to call. He said he was going to try to "encourage the company of at least thinking about a PR campaign in the future".
From your last post here, it sounds like you might have possibly pursuaded ADGO to think a little more about PR too. I'm just curious, are you "JII" on RB? It seams interest is building on the RB ADGO board a little bit?
You would think that Geoff Johnson from Catamount (who mentioned ADGO on CNBC Kudlow and Cramer) might also be pressuring them into becoming a little more IR friendly to?
In any case, ADGO looks like a good stock that I intend to hold for long-term gains.
Biophan news got picked up by CBS Marketwatch:
http://cbs.marketwatch.com/news/story.asp?guid={E7B95AFF-49AB-4A96-939B-25A1E2B19362}&siteid=mkt...
That should bring some new investors to Biophan, which is what they really need to get the stock to the next level. This CBS coverage is probably worth more than the "Monday morning effect" we were just fretting over IMO! It also got picked up by Axcess news...and I couldn't find any compensation statement anywhere on their website...so I assume it's also objective third party coverage?
Biophan seams to be playing this PR game a lot like BOCX did. BOCX issued a "shareholder update" on a Friday after the close, then the next Monday hit the wires with the results of their tests before the open. Biophan hit Friday morning with a shareholder letter, Friday after the close with an interesting (and unexpected) technology acquisition....and if you've read the shareholder letter, you should know there's more details coming about Boston Scientific. The question is when will they release that? I think a possitive joint press release with BSX will also bring a lot of new investors into Biophan.
Listen to the Biophan CEOcast interview when Weiner talks about their technology potentially enabling the use of real-time MRI for inserting stents (instead of x-ray). This is new rhetoric about Biophan's technology...and it makes me wonder what gave him those ideas...especially considering the detail he goes into?
http://www.ceocast.com/search.cfm
I do believe this company might be able to get the major listing they've been so eager to get and so outspoken about. It seamed ludicrous when they spoke about a major listing with their stock at 0.40.....but now they're showing that they might really have that kind of power under the hood IMO!
Good luck!
Catfish I don't understand why they release good news after the close on Fridays either? Hopefully they don't do that with the next Boston Scientific press release. I'm not making any assumptions with that statement because the shareholder letter this morning said "We will have more to say about our progress with Boston Scientific in the near future".
I have ADGO and EZEN in my retirement account....I like them both as long-term holds. EZEN.ob from $0.50, ADGO from $1.50.
I'm very heavily weighted in BIPH in my brokerage account from an average of $0.70. I believe Biophan will get a lot of new investors interested when they have their next joint press release with Boston Scientific.
Biophan news after close:
Biophan Announces Development of Breakthrough Long-Life Biothermal Battery
Friday May 14, 4:01 pm ET
Company Acquires Majority Interest in Biothermal Battery Nanotechnology Venture Targeting Approximately $500 Million Global Market
ROCHESTER, N.Y.--(BUSINESS WIRE)--May 14, 2004-- Biophan Technologies, Inc. (OTCBB: BIPH - News), a leading developer of next generation biomedical technology, announced today that it has acquired a majority interest in TE-Bio, LLC, a company developing a breakthrough, long-life power source for use in implanted medical devices, such as pacemakers, defibrillators, neurostimulators, and drug pumps.
ADVERTISEMENT
The technology is based on a patented innovation in the utilization of thermoelectric materials, using nanoscale-based, thin-film materials to convert thermal energy produced naturally by the human body into electrical energy. The resulting power can be used to "trickle charge" batteries for medium-power devices such as defibrillators, or directly power low-energy devices like pacemakers. The Company will be displaying the technology to over 6,000 healthcare professionals at the NASPE--Heart Rhythm Society's Heart Rhythm 2004 Conference, May 19-22, 2004 in San Francisco, CA.
TE-Bio is developing an implantable power system that has the potential to provide as much as a 30-year life--a five-fold increase in service life compared to existing technology. The technology is anticipated to dramatically extend the service life of neurostimulators and drug pumps that are used for treatment of tremors, diabetes, and chronic pain. Furthermore, since these devices can be implanted in young patients, the combination of TE-Bio technology and extended device life may reduce the number of replacement implants needed throughout a patient's life. For further information or to view the patent, please visit www.biophan.com/biothermal.php.
The use of implantable electronic medical devices is increasing worldwide due, in part, to the aging of the population and the increased use of these devices for both diagnostic and therapeutic treatments. However, existing systems share a major shortcoming - the need for a reliable electrical power source that does not require periodic surgical removal and replacement. Virtually all medical devices require replacement. It is estimated that neurostimulators, used to treat Parkinson's disease, last an average of three years; defibrillators last about five to six years, and pacemakers an average of about eight years.
Thermoelectric materials are special types of semiconductors that produce electricity when one side of the material is heated and the other is cooled. These materials have been used to generate electricity on spacecraft, such as the Voyager space probe, that are too far away from the sun for solar cells to operate. However, the low energy efficiency of existing materials has required very large temperature differences to produce a sufficient amount of usable power.
Recent advances in nanotechnology have now made new thermoelectric materials with the potential for generating sufficient electrical power for implantable medical devices, in part due to the ability to produce many more semiconductors on a surface.
TE-Bio holds a worldwide exclusive license to patent #6,640,137 "Biothermal Power Source for Implantable Devices" from Biomed Solutions, LLC.
"The realization of generating enough energy to power a pacemaker, or extend the life of a defibrillator, from the heat differential in our bodies, has been brought within striking distance by the remarkable revolution in materials science and advances in nanotechnology," stated Michael Weiner, CEO of Biophan.
Conference Call and Webcast
The Company will discuss the impact and market opportunity represented by this breakthrough technology on a conference call and webcast on Tuesday, May 18 at 12:00 pm Eastern. Following the discussion, Michael Weiner, president of Biophan, and other members of the executive management team will be available to answer questions regarding the technology and other technology which the Company is currently developing. Participants may ask questions during the Q & A segment of the call or, if they prefer, may e-mail questions in advance of the call to Randy Lewis, senior vice president of Trilogy Capital Partners, randy@trilogy-capital.com. To access the call, Investors should call at (888) 423-3274, code 731878 or from an international location by calling (651) 291-0278.
Catfish BIPHs last SB-2 said Boston Scientific had until May 15th to negotiate to secure firts rights to BIPHs technology.....so keep your horizons open....if another joint release from BSX comes out BIPH could make some significant gains IMO.
Furthermore, the company keeps refering to their ambition to get listed on a major exchange.....it would be awful gutsy of them to keep that rhetoric going if they didn't have an ace in the hole IMO.
I hope that position works out for you.....I added to my position at $1.20 a few weeks ago....and have the motivation for a quick big profit...hasn't worked out yet...but I believe it will in time.
Good luck to you!
PSOL: Catfish have you given this one a look?
I also like PSOL for a long-term hold in my IRA. They do billing for Time Warner's VOIP services that are now being slowly deployed accross the country. Here's an excerpt of post 970 from RB from "TALLPAUL_30". These are some good details regarding Time Warner's VOIP roll-out:
The next few quarter's revenue will grow based on the number of cities online for a full quarter.
The 4th Quarter had only Portland, ME region, the 1st Quarter added the Carolina's.
The 2nd Quarter will have Kansas City, Columbus, OH, Rochester, NY for the full quarter.
While the new rollout cities will add to the revenues, the existing cities will continue to build as new customers switch from RBOC's (Regional Bell's).
This is only for Time Warner, what revenues will accrue from the rollout's of the other "unnamed Tier 1 Cable MSO could have a compounding effect.
TALLPAUL also made some good specualation about who the other new "Teir 1 MSO customer" could be in post 1018 on RB:
From C/Net News.Com, November, 2003 Publication
"Most U.S. cable providers are launching VoIP plans to challenge the telephone companies' stranglehold on the local and long-distance phone market. Cablevision is the second major U.S. cable provider to make a bigger commitment to VoIP in less than a month."
"In late October, Time Warner Cable announced plans to expand its "Digital Phone" service to four more cities."
"Meanwhile, the nation's top cable broadband providers, Cox Communications and Comcast, are still testing the technology, and both say they won't implement it until at least late next year."
It has to be Cablevision, since they announced their VOIP rollout in November, 2003.
Cox and Comcast are deferring until late 2004, or possibly later, plus Adelphia won't consider it while still in Chapter 11.
Their is no one left to qualify as "the other tier 1 Cable MSO", because they're the Big 5.
Cablevision is offering their VOIP service to 1,000,000 high-speed internet customers in the lucrative NYC Metro market.
It only gets better for the home-team.
TP
EZEN: Great earnings! The second consecutive quarter of possitive earnings. New DOD orders in excess of $4.5 mil. announced the past month lead me to believe the numbers should continue to get better there for at least the next couple of quarters. The government has contracted them to improve their product too, so I would expect orders to continue or possibly increase once the modifications are made to Infoworkspace.
As a very worst case scenario, assume the $0.07 they put up the past two quarters is all they will earn this year. Then a P/E of 10 would make this stock woth $0.70.
This was another excellent early foresight by GPG. That guy is incredible at finding these good situations early. I don't know if he's man or machine! :)
BLLI: I've had a bid on it for the past week at $0.75 and it hasn't traded one single share this whole time. Someone please sell me your shares at $0.75 :)
MYMX: MYMX has settled down now. Here's why this might be a good long shot:
This Friday, April 16th 8k caused a little surge in this stock:
ITEM 5. OTHER EVENTS.
Mymetics Corp. and its French partner Protein'eXpert SA are proud to announce that recent work has positively demonstrated the biological functionality of the large scale, conformational mimicry between the gp41 HIV transmembrane protein and IL-2, a key protein sometimes referred to as "the immune system's conductor".
Mymetics is convinced that understanding the functionality of such large scale, conformational mimicry, which it first identified in 1997, opens the way to an original and innovative approach to developing vaccines against AIDS.
Mymetics Corp. and Protein'eXpert SA have been able to produce at low cost the synthetic, trimeric and soluble gp41 proteins used in such work and which we believe to be potential AIDS vaccine candidates.
Mymetics holds several patents and patent applications based on this discovery, which we believe to be reinforced and vindicated by the above referenced results.
This statement is from their 2/20/04 8k:
On January 9, 2004, the Board of Directors appointed Professor Marc Girard, DVM, D. Sc., former Head of the Laboratory of Molecular Virology at the Pasteur Institute in Paris (France), former Director of the European Research Center for Virology and Immunology (CERVI) in Lyon (France), former Head of the HIV Task Force at the French National Agency for AIDS Research (ANRS), Paris, former Director General of the Merieux Foundation in Lyon (France), former Chairman of the European Consortium for an HIV Vaccine (EuroVac), Brussels, as Head of Vaccines Development, effective January 15, 2004 on a 50%, part time basis.
This statement is from Mymetics quarterly report filed 3/30/04:
Initiation of partnership discussion with pharmaceutical companies, all world leaders in the respective human or veterinary vaccine related (AIDS) fields. [DISCUSSIONS WITH THREE SUCH POTENTIAL PARTNERS WILL BE CONDITIONNED BY THE INITIAL RESULTS FROM OUR RECENTLY INITIATED SCIENTIFIC TRIALS, SOME OF WHICH COULD HAVE BEEN COMPLETED LONG BEFORE JULY 31, 2003]
As of March 18, 2004, there were 59,394,454 shares outstanding. 80,000,000 authorized. Insiders control approximately 50% of the current OS. At Friday's closing PPS of $0.25 the market cap was $15,000,000
This is all incredibly possitive stuff, so why isn't the company worth a little more that $10,000,000? Because there's several risk factors characterized by this statement, also from the last quarterly report:
Despite limited means and impressive hurdles to overcome, we have been able since July 31, 2003 to graduate from an assured crash to a (still) bumpy ride. In more practical terms, we have been able to (i) attract four new investors, (ii) remove all immediate threats of bankruptcy or forced liquidation, (iii) normalize our relations with our critical suppliers of scientific or corporate services, (iv) launch critical scientific tests aimed at reinforcing our position in the discussions we have initiated with certain pharmaceutical companies, (v) gain reasonable assurance that results will be encouraging, never forgetting however that biology remains a complex and largely unpredictable science, and (vi) applied for grants from public and private donors.
We intend to devote in the future more time and efforts to grant applications (which are very time consuming), as such sources of funds are non dilutive by essence. We believe that our chances of obtaining such funds in a reasonable time span are high enough to continue justifying our directors' and officers' efforts and personal sacrifices.
Despite our efforts and achievements, we have no reasonable hope to be able to reimburse the Euro 3.2 million credit facility due to MFC Bank on or before its present due date of June 30, 2004, and have no assurance that MFC Bank will accept to renegotiate it on terms acceptable to us.
THERE'S OBVIOUSLY SOME SIGNIFICANT RISKS REMAINING HERE, SO INVEST ACCORDINGLY!!
Don't put all your eggs in one basket. I put about 3% of my eggs in the basket for the longshot.
Thanks Gary for finding this one!
ISON: Looks like most of the float has traded in the past two days. Things are settling down and I think I'll be adding to my position here in the coming week or two. I would think it should be set to go higher on any good news. This is a great play with some qualified board members, some great technology, and a hand in semiconductors (SI-32), bio-tech (PET scanning), and bomb detection (neutron based detection).
Here's yesterday's release:
Isonics Corporation Announces Strategic Initiatives for Fiscal Year 2005
Monday April 26, 4:01 pm ET
GOLDEN, Colo.--(BUSINESS WIRE)--April 26, 2004--Isonics Corporation (NASDAQ: ISON - News), a leader in the development of isotopically engineered semiconductor materials, a supplier of silicon-on-insulator (SOI) wafers and isotopes for life sciences and health care applications, announced today its Strategic Initiatives for its 2005 fiscal year. The announcement was made by James E. Alexander, chairman, president and CEO of Isonics.
Mr. Alexander stated, "With our year-end coming to a close on April 30, and Isonics' strategic plan successfully being executed, we are enthusiastically announcing our strategic initiatives - which outline what we believe to be a compelling vision for the future of the company - for the upcoming 2005 fiscal year."
During FY 2004 we successfully:
Solidified our life sciences segment by signing long-term supply agreements with existing and new customers for oxygen-18 and extending the joint production agreement with our Russian supplier, Global Scientific Technologies.
Further developed our silicon-on-insulator (SOI) wafer manufacturing processes and signed a letter-of-intent to acquire the silicon wafer manufacturing business and related assets from EnCompass Materials Group Ltd. (EMG) of Vancouver, Washington, where (if we complete the acquisition) we plan to implement that SOI technology in high-volume manufacturing.
Made significant advances with high thermal conductivity silicon-28 in customer evaluations, one of which may lead to our first commercial win
Received a U.S. patent for isotopically engineered wafers, "Semiconductor Wafers with Integrated Heat Spreading Layer"
Solidified our position in the homeland security market through the Company's subsidiary IUT Detection Technologies and its advanced neutron-based technology for detection of explosives and chemical/biological agents
Raised over $5.5 million in equity financing which has positioned the Company for boldly executing our strategic initiatives
Strategic Initiative 1 - Commitment to Grow the Life Sciences Segment
Our Life Sciences segment, which serves the healthcare industry by providing products for the imaging and treatment of cancer, is a solid business. Our leading product is Oxygen-18 ,which is the essential raw material that supports the fast growing positron emission tomography (PET) imaging technology. This business, while solid, has shown growth only commensurate with the industry. In fiscal 2005, we will begin executing plans that, we believe, will triple segment revenues within three years while generating improved gross margins.
We will do this by executing plans to broaden our product offerings and by vertically integrating, either forward or backward or both, to add value to our products and better serve our customers. Related to this will be the diversification of isotope supply, which now is exclusively from the former Soviet Union, but will be expanded to European and North American sources as well. However, we will continue to seek those new isotope products from Russia that also complement the objectives of this strategic initiative.
Strategic Initiative 2 - Invest in Silicon-28 Commercialization
Isotopically-pure silicon-28 has superior thermal properties compared to normal silicon. As heat is becoming an ever-increasing problem to chip designers, silicon-28 is attracting more and more interest. Customers are beginning to see meaningful temperature benefits in actual products made from Isonics' supplied silicon-28 epitaxial wafers. It appears that the more silicon-28 built into a wafer, the larger the thermal benefit obtained.
Isonics believes that silicon-28 wafer can be sold at a substantial premium to the price of a normal silicon wafer silicon-28 and still be a commercial success. However, pricing will dictate the amount of market that we may penetrate. Therefore, Isonics will institute a silicon-28 cost reduction strategic initiative. We will invest in commercializing a promising new isotope enrichment technology as well as improving the economics of the mature gas centrifuge technology, which presently provides our silicon-28. We will also look at ways to improve the efficiency of deposition of epitaxial silicon-28. Doubling the efficiency from the industry typical 10% to 20% by process and equipment innovations would reduce our cost by 50%. To the extent we are successful in reducing costs, our market penetration and profitability will be greatly influenced.
Strategic Initiative 3 - Silicon-on-Insulator Wafer Manufacturing
Isonics' leadership position in its market segments is not only dependent upon superior materials, but the processes used to manufacture products, particularly in the price-sensitive semiconductor market.
Last month, we announced that we signed a letter of intent to acquire the silicon wafer manufacturing business and related assets from EnCompass Materials Group Ltd. (EMG) of Vancouver, Washington. EMG manufactures silicon test wafers and provides wafer re-cycling services for leading semiconductor manufacturers. We want to acquire this company to exploit its people and manufacturing systems to produce higher margin SOI wafers using Isonics' developed intellectual property, such as our Sigma I process that is capable of transferring silicon layers only tens' of nanometers in thickness.
With this ISO-qualified manufacturing facility under our control, we can then confidently accept large commercial orders, which we now routinely decline. Growth of revenues in the segment will play a major role in driving the overall company toward profitability this fiscal year.
Strategic Initiative 4 - Homeland Security - Neutron Detection Technology
Isonics, through its IUT Detection Technologies subsidiary, has been quietly promoting its technology for neutron-based detection technology that we believe is useful for identification of explosive and chemical and biological agents. In fiscal 2005 we are committed to actualizing the value of this technology to our shareholders. We are pursuing strategic relationships from leading industry participants, as well as direct financial investments into the subsidiary. No specific plan has been established at this time, but management is dedicated in fiscal 2005 to completing one or more transactions that will provide the financial and personnel resources necessary to bring this technology to the commercial level.
Summary
Isonics is a diverse technology company, with burgeoning opportunities in semiconductors, pharmaceuticals, and homeland security. Much of our technology portfolio is based on nanotechnology processes or are enablers for the manufacture of nanotechnology devices. Our motto -- "building businesses one atom at a time" -- is reflective of this.
Mr. Alexander continued: "We are extraordinarily enthusiastic about our early successes and the numerous milestones we have achieved to date. Most importantly, Isonics looks forward to substantial growth in revenues, earnings and, ultimately, in shareholder value."
About Isonics Corporation
Isonics Corporation is divided into two segments: (1) Isonics Semiconductor and (2) Isonics Life Sciences. Isonics is a world leader in isotopically engineered materials and through its semiconductor division produces isotopically pure silicon-28 chemicals and wafers for the semiconductor industry. Through advances in nanotechnology, the Company is also focused on research and development opportunities for further, value-added product and application development. Isonics' Life Sciences division markets and sells stable isotopes for the health care industry such as carbon-13 for diagnostic breath tests and drug design, and radioisotopes and stable isotopes, such as oxygen-18 for positron emission tomography (PET) imaging. Stable isotopes can be thought of as ultra pure materials. This high degree of purification provides enhanced properties as compared to natural materials. Additional information may be obtained at the Company's Web site at http://www.isonics.com.
PHPG: MMs are stepping over my bid to buy 2000 at $1.15 to fill someone at $1.05.
Ken, that's one long hold! Unfortunately, I would have needed to use my busboy tip money to buy back in 1993 :) Instead I used it all on books, beer, and tuition. That investment payed-off in a library of unused science text books, plenty of extra calories, and a diploma that took me the the heights of the hazardous waste world! Yes, I have the privelaged distinction of saying I worked at America's Nuclear Proving Ground, the Nevada Test Site (among hundereds of other devastated sites created by our government and Fortune 500 companies)!
In my travels, readings, and career dilligence I never came accross TVIN......but the revenues speak for themselves now....may as well hold for another year or two for what should be an easy double from here. I hope you took advantage of the opportunity to average down between 1996 and 2001!
Good luck in all you investments!
TVIN....been watching this one since $0.20...and because I never saw their products advertised or profiled in any of my haz. waste proffessional journals I never thought they were going to be able to penetrate the market. Boy was I was wrong!
Here's a good post from the SI Microcap Kitchen. Everyone's hindsight is 20/20; but take a look at this foresight...like from the hubbel telescope! It is a great privelage for us to be able to watch this guy!
To:GARY P GROBBEL who wrote (2850)
From: GARY P GROBBEL Monday, Sep 17, 2001 11:01 AM
View Replies (2) / Respond to of 20133
if you don't have a lot of cash on hand here is one way to go...TVIN otc bb .14...read full release:
TVI Corporation Reports Record Revenue and Continuing Profitability for Second Quarter
GLENN DALE, Md.--(BUSINESS WIRE)--Aug. 8, 2001--TVI Corporation announced Wednesday that its revenues for the quarter ending June 30 had exceeded one million dollars, the first such quarter in many years.
Unaudited financial results for three and six month periods ending June 30, 2001 and 2000 were as follows:
3 mos 2001 3 mos 2000 6 mos 2001 6 mos 2000
----------- ----------- ----------- -----------
Revenue $ 1,032,079 $ 654,765 $ 2,026,217 $ 1,502,072
Cost of Goods 515,317 312,897 1,024683 692,072
Gross Profit 515,762 341,868 1,001,534 810,000
S,G,&A
Expense 233,318 212,441 622,408 432,262
Operating
Income
(Loss) 184,484 129,427 379,126 377,738
Other Income
(Expense) 00 102,644 00 102,644
Option
Exercise
Expense (20,750) 00 (20,750) 00
Net Interest
Expense (627) (2,524) (10,567) (4,862)
Net Income $ 163,107 $ 229,547 $ 347,808 $ 469,076
Earnings per
share .006 .009 .014 .019
Shares
Outstanding 25,246,035 24,401,307 25,246,035 24,401,307
Allen Bender, TVI's CEO, noted that second quarter results had met budget and were consistent with previous quarters' results. ``We continue to concentrate on developing new revenue streams while maintaining our historical markets,'' he said.
Mr. Bender noted that the company's strategic development plan had been discussed at the Annual Meeting on June 6, and that minutes of the meeting were available on the company's website on the Internet.
The company noted that revenues were higher as a result of continuing acceptance of its Counter Terrorism products and specifically its mass casualty decontamination equipment. Sales of thermal products remain depressed due to severe funding limits at the ranges.
Mr. Bender noted that detailed quarterly financial data including management's discussion and analysis will be included in Form 10-QSB to be filed shortly with the SEC. The report will be available from EDGAR on the Internet.
TVI is a leading manufacturer of quick erect tents and signage, casualty decontamination systems, and thermal targets. Its stock trades on the OTC Bulletin Board under the symbol TVIN. More information is available at the company's website at www.tvicorp.com.
--------------------------------------------------------------------------------
Contact:
TVI Corporation
Allen Bender, 301/352-8800
Email this story - Most-emailed articles - Most-viewed articles
--------------------------------------------------------------------------------
More Quotes and News: TVI Corp (OTC BB:TVIN.OB - news)
Related News Categories: banking, chemicals, earnings, environmental
SEHO:
I spoke to SEHO IR this morning. Essentially, what I got from the conversation was that they've withdrawn their SB-2 in order to consider a private placement on more favorable terms.
They've also just begun to discuss potential liscensing of their biometric vehicle patent with existing customers (FedEx and AA) and have initiated contact with some of the major vehicle manufacturers.
I didn't get anything too concrete from the conversation; but IMHO these general developments are worth more than the current $6M market cap.
SEHO: I'm not sure why SEHO would cancel their financing? They need some cash to keep paying the slaries and the rent? They only had $91k at the end of December, that's not going to hold them over too long. So did they have a better financing offer? Or do they see more revenue coming down the pipe?
hmmm? I'll give a call and try to get some answers and let you know if I find anything out.